CN1586533A - 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 - Google Patents
一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 Download PDFInfo
- Publication number
- CN1586533A CN1586533A CN 200410062488 CN200410062488A CN1586533A CN 1586533 A CN1586533 A CN 1586533A CN 200410062488 CN200410062488 CN 200410062488 CN 200410062488 A CN200410062488 A CN 200410062488A CN 1586533 A CN1586533 A CN 1586533A
- Authority
- CN
- China
- Prior art keywords
- fructus
- radix
- substitute
- equivalent
- schisandrae chinensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 210000004369 blood Anatomy 0.000 title abstract description 23
- 239000008280 blood Substances 0.000 title abstract description 23
- 210000003734 kidney Anatomy 0.000 title abstract description 12
- 230000017531 blood circulation Effects 0.000 title abstract description 7
- 238000005728 strengthening Methods 0.000 title abstract description 5
- 210000000952 spleen Anatomy 0.000 title abstract description 3
- 230000001737 promoting effect Effects 0.000 title abstract 2
- 239000002184 metal Substances 0.000 title 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 63
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 62
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 62
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 62
- 235000008434 ginseng Nutrition 0.000 claims abstract description 62
- 230000000694 effects Effects 0.000 claims abstract description 52
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 201000007094 prostatitis Diseases 0.000 claims abstract description 11
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims abstract description 7
- 230000001900 immune effect Effects 0.000 claims abstract description 6
- 241000208340 Araliaceae Species 0.000 claims description 60
- 235000003935 Hippophae Nutrition 0.000 claims description 35
- 241000229143 Hippophae Species 0.000 claims description 35
- 239000009636 Huang Qi Substances 0.000 claims description 35
- 239000002994 raw material Substances 0.000 claims description 33
- 206010036596 premature ejaculation Diseases 0.000 claims description 11
- 239000002131 composite material Substances 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 230000001568 sexual effect Effects 0.000 claims description 8
- 206010008132 Cerebral thrombosis Diseases 0.000 claims description 6
- 201000001429 Intracranial Thrombosis Diseases 0.000 claims description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 5
- 208000007443 Neurasthenia Diseases 0.000 claims description 5
- 206010039966 Senile dementia Diseases 0.000 claims description 5
- 206010003549 asthenia Diseases 0.000 claims description 5
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 230000036737 immune function Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000016255 tiredness Diseases 0.000 claims 1
- 230000003867 tiredness Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 170
- 240000005373 Panax quinquefolius Species 0.000 abstract 3
- 244000241838 Lycium barbarum Species 0.000 abstract 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract 2
- 235000011034 Rubus glaucus Nutrition 0.000 abstract 2
- 244000235659 Rubus idaeus Species 0.000 abstract 2
- 235000009122 Rubus idaeus Nutrition 0.000 abstract 2
- 240000006079 Schisandra chinensis Species 0.000 abstract 2
- 235000008422 Schisandra chinensis Nutrition 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 241000893536 Epimedium Species 0.000 abstract 1
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 208000013507 chronic prostatitis Diseases 0.000 abstract 1
- 235000018905 epimedium Nutrition 0.000 abstract 1
- 208000033065 inborn errors of immunity Diseases 0.000 abstract 1
- 230000003340 mental effect Effects 0.000 abstract 1
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 40
- 230000007812 deficiency Effects 0.000 description 27
- 229940079593 drug Drugs 0.000 description 25
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 20
- 238000011282 treatment Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 16
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 15
- 230000003203 everyday effect Effects 0.000 description 15
- 239000000787 lecithin Substances 0.000 description 15
- 229940067606 lecithin Drugs 0.000 description 15
- 235000010445 lecithin Nutrition 0.000 description 15
- 210000000265 leukocyte Anatomy 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 210000003127 knee Anatomy 0.000 description 13
- 238000000034 method Methods 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 208000009205 Tinnitus Diseases 0.000 description 11
- 210000000038 chest Anatomy 0.000 description 11
- 210000002381 plasma Anatomy 0.000 description 11
- 231100000886 tinnitus Toxicity 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 229960003604 testosterone Drugs 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 208000019914 Mental Fatigue Diseases 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 235000019634 flavors Nutrition 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000000115 thoracic cavity Anatomy 0.000 description 7
- 102000010909 Monoamine Oxidase Human genes 0.000 description 6
- 108010062431 Monoamine oxidase Proteins 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 230000002269 spontaneous effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000000059 Dyspnea Diseases 0.000 description 5
- 206010013975 Dyspnoeas Diseases 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 208000012886 Vertigo Diseases 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 210000002307 prostate Anatomy 0.000 description 5
- 230000009182 swimming Effects 0.000 description 5
- 231100000889 vertigo Toxicity 0.000 description 5
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
- CMVHOLZLFLESKY-UHFFFAOYSA-N Anisodine Natural products CN1C2CC(CC1C3OC23)C(=O)OC(O)(CO)c4ccccc4 CMVHOLZLFLESKY-UHFFFAOYSA-N 0.000 description 4
- 206010040007 Sense of oppression Diseases 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- JEJREKXHLFEVHN-QDXGGTILSA-N anisodine Chemical compound C1([C@](O)(CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 JEJREKXHLFEVHN-QDXGGTILSA-N 0.000 description 4
- 230000002567 autonomic effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- -1 lipid peroxide Chemical class 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 210000004908 prostatic fluid Anatomy 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 208000013220 shortness of breath Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 240000007711 Peperomia pellucida Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000000386 athletic effect Effects 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000003163 gonadal steroid hormone Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 229940039009 isoproterenol Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 206010029446 nocturia Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 210000001840 diploid cell Anatomy 0.000 description 2
- 235000013345 egg yolk Nutrition 0.000 description 2
- 210000002969 egg yolk Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010037528 lactotropin Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical class O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 239000000745 gonadal hormone Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000007105 physical stamina Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
病例 | 治疗前 | 治疗后第一疗程 | 治疗后第二疗程 |
12例 | 卵磷脂小体≥50%白细胞≥10/HP | 卵磷脂小体≥70%白细胞≥5-10/HP | 卵磷脂小体≥80%白细胞≥0-1/HP |
10例 | 卵磷脂小体≥30%白细胞≥20/HP | 卵磷脂小体≥80%白细胞≥3-5/HP | 卵磷脂小体≥80%白细胞≥0-1/HP |
2例 | 卵磷脂小体≥50%白细胞≥3-5/HP | 化验标本未取出 | 卵磷脂小体≥70%白细胞≥0-1/HP |
4例 | 卵磷脂小体≥30%白细胞≥2-3/HP | 卵磷脂小体≥30%白细胞≥2-5/HP | 卵磷脂小体≥30%白细胞≥3-5/HP |
总有效率:86.71%(注:取前列腺标本失败即化验标本未取出) |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410062488 CN1245189C (zh) | 2004-07-12 | 2004-07-12 | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410062488 CN1245189C (zh) | 2004-07-12 | 2004-07-12 | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1586533A true CN1586533A (zh) | 2005-03-02 |
CN1245189C CN1245189C (zh) | 2006-03-15 |
Family
ID=34603713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410062488 Expired - Lifetime CN1245189C (zh) | 2004-07-12 | 2004-07-12 | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1245189C (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100464776C (zh) * | 2006-01-10 | 2009-03-04 | 天津市东方虹膜医学技术研究开发中心 | 扶正清浊散 |
CN101760390B (zh) * | 2009-12-10 | 2012-05-30 | 神农架神农氏生物开发有限公司 | 一种养身酒的生产方法 |
CN103239509A (zh) * | 2013-05-06 | 2013-08-14 | 陕西立众制药有限公司 | 一种用于益气健脾、补肾宁心的中药组合物及其制备方法 |
CN104189695A (zh) * | 2014-09-17 | 2014-12-10 | 兰成然 | 一种主治尿失禁的中草药制剂及其制作方法 |
CN104645229A (zh) * | 2015-02-04 | 2015-05-27 | 北京全净通一科技有限公司 | 一种五行药浴散及制备方法 |
CN105031203A (zh) * | 2015-08-21 | 2015-11-11 | 河北工程大学 | 治疗老年痴呆的中药组合物 |
CN107495367A (zh) * | 2017-08-24 | 2017-12-22 | 四川省中医药科学院 | 一种提高耐缺氧能力的食品、保健品或药物组合物及其制备方法和用途 |
CN108578522A (zh) * | 2018-07-02 | 2018-09-28 | 成荣富 | 一种治疗前列腺炎的中草药 |
CN109793834A (zh) * | 2019-03-30 | 2019-05-24 | 漯河医学高等专科学校 | 一种提高免疫力的中药配方 |
CN114010740A (zh) * | 2021-11-26 | 2022-02-08 | 建和复元生物科技(深圳)有限公司 | 一种具有脱发再生修护前列腺功能的药酒 |
-
2004
- 2004-07-12 CN CN 200410062488 patent/CN1245189C/zh not_active Expired - Lifetime
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100464776C (zh) * | 2006-01-10 | 2009-03-04 | 天津市东方虹膜医学技术研究开发中心 | 扶正清浊散 |
CN101760390B (zh) * | 2009-12-10 | 2012-05-30 | 神农架神农氏生物开发有限公司 | 一种养身酒的生产方法 |
CN103239509A (zh) * | 2013-05-06 | 2013-08-14 | 陕西立众制药有限公司 | 一种用于益气健脾、补肾宁心的中药组合物及其制备方法 |
CN103239509B (zh) * | 2013-05-06 | 2014-09-03 | 陕西立众制药有限公司 | 一种用于益气健脾、补肾宁心的中药组合物及其制备方法 |
CN104189695A (zh) * | 2014-09-17 | 2014-12-10 | 兰成然 | 一种主治尿失禁的中草药制剂及其制作方法 |
CN104645229A (zh) * | 2015-02-04 | 2015-05-27 | 北京全净通一科技有限公司 | 一种五行药浴散及制备方法 |
CN104645229B (zh) * | 2015-02-04 | 2018-02-13 | 北京全净通一科技有限公司 | 一种五行药浴散及制备方法 |
CN105031203A (zh) * | 2015-08-21 | 2015-11-11 | 河北工程大学 | 治疗老年痴呆的中药组合物 |
CN107495367A (zh) * | 2017-08-24 | 2017-12-22 | 四川省中医药科学院 | 一种提高耐缺氧能力的食品、保健品或药物组合物及其制备方法和用途 |
CN108578522A (zh) * | 2018-07-02 | 2018-09-28 | 成荣富 | 一种治疗前列腺炎的中草药 |
CN109793834A (zh) * | 2019-03-30 | 2019-05-24 | 漯河医学高等专科学校 | 一种提高免疫力的中药配方 |
CN114010740A (zh) * | 2021-11-26 | 2022-02-08 | 建和复元生物科技(深圳)有限公司 | 一种具有脱发再生修护前列腺功能的药酒 |
Also Published As
Publication number | Publication date |
---|---|
CN1245189C (zh) | 2006-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1709497A (zh) | 一种苗药组合物及其应用 | |
CN1586533A (zh) | 一种扶正固本、健脾益肾,宁心安神,活血化淤的组合物 | |
CN1212856C (zh) | 一种治疗咽喉炎的药物组合物的制备方法 | |
CN1593583A (zh) | 治疗骨折的复方制剂及其制备方法 | |
CN1290553C (zh) | 一种治疗月经过多的药物组合物及其制备方法 | |
CN1294936C (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN1679802A (zh) | 一种壮腰健肾制剂和制备方法 | |
CN1596939A (zh) | 一种治疗心脑血管疾病的中成药及其制备方法 | |
CN1112439A (zh) | 治疗糖尿病的中药及其生产方法 | |
CN1323692C (zh) | 治疗肾虚腰痛的药物组合物及其制备方法 | |
CN1923270A (zh) | 治疗良性前列腺增生症的药物及其制备方法 | |
CN1296080C (zh) | 清肝降压胶囊及其制备方法 | |
CN1220163A (zh) | 治疗经前期紧张症的药物 | |
CN1507352A (zh) | 植物药复方及其应用 | |
CN1778358A (zh) | 一种治疗前列腺增生的药物及其制备方法 | |
CN1726934A (zh) | 血府逐瘀药物组合物在制备降血脂药物中的应用 | |
CN1631895A (zh) | 苦杏仁苷的制备方法和苦杏仁苷在制备促进心脑胰及伤口血液循环的苦杏仁苷制剂中的应用 | |
CN1169569C (zh) | 治疗乳腺增生病的中药组合物及其制备方法 | |
CN1104527A (zh) | 参麦注射液在制造抗癌药物中的应用 | |
CN1554407A (zh) | 一种清肺化痰止咳平喘的药物及其制备方法 | |
CN1733116A (zh) | 治疗高血压症的药物制剂及其制备方法 | |
CN1616003A (zh) | 一种治疗前列腺炎的药物 | |
CN1565530A (zh) | 一种治疗尿失禁的药物及其制备方法 | |
CN101062027A (zh) | 牛磺酸和治疗心脑血管疾病的药物的组合物 | |
CN1631413A (zh) | 一种治疗慢性结肠炎的药物及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060315 Termination date: 20120712 |
|
C49 | Reinstatement of patent right or utility model | ||
RR01 | Reinstatement of patent right |
Former decision: cessation of patent right due to non-payment of the annual fee Former decision publication date: 20130904 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20210622 Address after: 102629 2-1113, yard 9, Huatuo Road, Daxing District, Beijing Patentee after: Sun Shuming Patentee after: Liu Hongwei Address before: 100044, room 6, building 253, Yiyuan garden, Beijing Jiaotong University, Beijing, Haidian District Patentee before: Sun Shuming |
|
TR01 | Transfer of patent right | ||
CX01 | Expiry of patent term |
Granted publication date: 20060315 |
|
CX01 | Expiry of patent term |